New drug EP395 shows promise in taming lung inflammation
NCT ID NCT05516316
First seen Apr 30, 2026 · Last updated May 17, 2026 · Updated 2 times
Summary
This study tested a new drug called EP395 in 49 healthy adults to see if it could reduce inflammation in the lungs. Participants inhaled a substance that causes temporary airway inflammation, and those who received EP395 were expected to have less inflammation than those who received a placebo. The goal is to develop a treatment for chronic obstructive pulmonary disease (COPD), a condition where lung inflammation is a major problem.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fraunhofer Institute for Toxicology and Experimental Medicine ITEM
Hanover, 30625, Germany
Conditions
Explore the condition pages connected to this study.